Effect of valsartan-eluting stents on the expression of angiotensin II type 2 receptor

作     者：WANG Lei LI Gui-hua CHEN Hui LI Hong-wei ZHAO Lin YAO Dao-kuo DING Rong-jing JIA San-qing 

作者机构：Cardiovascular Center of Beijing Friendship Hospital Capital University of Medicine Sciences Beijing 100050 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2006年第119卷第7期

页      面：601-604页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：The study was supported by a grant from Beijing Municipal Nature Science Fund (No. 7042021) 

主　　题：eluting stent valsartan angiotensin Ⅱ neointima restenosis 

摘      要：Percutaneous coronary intervention （PCI） with drug-eluting stent implantation has been provedefficient to reduce complications and restenosis in type B2/C lesions compared with bare stent, since the major drawback of the latter technique is intimal hyperplasia from the vessel media, which significantly cause in-stent restonosis. Despite the beneficial effects on the renin-angiotensin-aldosterone （RAAS） system, the role of angiotensin-converting enzyme （ACE） inhibitors after PCI is still unclear. However, first results of angiotensin receptor antagonist （valsartan） after stent implantation in the VaI-PREST1 and VALVACE2 trials have indicated the systemic pharmacological effect in the prevention of in-stent-restenosis. Up to our knowledge, whether local treatment of valsartan by implanting drug-eluting stent can generally prevent restenosis by inhibiting intimal hyperplasia has not been explored.